Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|April 3, 2012
Conference Coverage From the ATA Annual Meeting
Author(s)Onclive Team
Conferencd coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA).
Advertisement
Live coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA) from September 19-23, 2012, at the Hilton Quebec and Quebec City Convention Centre, Quebec City, PQ, Canada.
The meeting featured cutting-edge educational sessions, great networking opportunities, and unmatched collegiality.
Find out more at
Not signed up to receive OncLive emails? Make an account today to make sure you don't miss updates from our conference coverage.
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5